{"transactions":[{"id":4622958,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Stock Option","published_at":"2026-09-18T23:45:38.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in monthly increments over a period of one year from the grant date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and R. Thorvald Nagel, who serves on the Issuer's board of directors and as a Principal of Partners, pursuant to which Mr. Nagel is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Nagel disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":25370,"derivative":{"exercise_price":10.12,"expiration_date":"2036-09-16","underlying":"Common Stock, $0.0001 par value","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0000921895-26-002590","document":"form407422010_09182026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526002590/form407422010_09182026.xml","form_type":"4"}},{"id":708530,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2026-07-16T21:02:46.000Z","date":"2026-07-14","kind":"other","planned":false,"acquired":false,"shares":772000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among the Issuer, Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities held in certain Partners managed accounts (the \"Partners Managed Accounts\"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities held in certain Partners managed accounts (the \"Partners Managed Accounts\"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-26-001823","document":"form407422010_07162026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001823/form407422010_07162026.xml","form_type":"4"}},{"id":708529,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2026-07-16T21:02:46.000Z","date":"2026-07-14","kind":"other","planned":false,"acquired":false,"shares":412000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among the Issuer, Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-26-001823","document":"form407422010_07162026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001823/form407422010_07162026.xml","form_type":"4"}},{"id":708528,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2026-07-16T21:02:46.000Z","date":"2026-07-14","kind":"other","planned":false,"acquired":false,"shares":2773545,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among the Issuer, Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-26-001823","document":"form407422010_07162026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001823/form407422010_07162026.xml","form_type":"4"}},{"id":708527,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2026-07-16T21:02:46.000Z","date":"2026-07-14","kind":"other","planned":false,"acquired":false,"shares":3635758,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among the Issuer, Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-26-001823","document":"form407422010_07162026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001823/form407422010_07162026.xml","form_type":"4"}},{"id":725874,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2026-06-26T22:48:12.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":51858,"price":106.5,"value":5522877.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities held in a certain Partners managed account (the \"Partners Managed Account\"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities held in a certain Partners managed account (the \"Partners Managed Account\"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account."}],"balance_after":78787,"source":{"system":"sec-edgar","filing":"0000921895-26-001688","document":"form407422010_06262026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001688/form407422010_06262026.xml","form_type":"4"}},{"id":725873,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2026-06-26T22:48:12.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":113289,"price":106.5,"value":12065278.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":240123,"source":{"system":"sec-edgar","filing":"0000921895-26-001688","document":"form407422010_06262026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001688/form407422010_06262026.xml","form_type":"4"}},{"id":725872,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2026-06-26T22:48:12.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":627597,"price":106.5,"value":66839080.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":1592261,"source":{"system":"sec-edgar","filing":"0000921895-26-001688","document":"form407422010_06262026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001688/form407422010_06262026.xml","form_type":"4"}},{"id":725871,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2026-06-26T22:48:12.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":837914,"price":106.5,"value":89237841.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":1960881,"source":{"system":"sec-edgar","filing":"0000921895-26-001688","document":"form407422010_06262026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001688/form407422010_06262026.xml","form_type":"4"}},{"id":727010,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T22:58:13.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":6068,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":6068,"derivative":{"exercise_price":99.87,"expiration_date":"2036-06-23","underlying":"Common Stock, $0.0001 par value","underlying_shares":6068},"source":{"system":"sec-edgar","filing":"0000921895-26-001680","document":"form407422010_06252026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001680/form407422010_06252026.xml","form_type":"4"}},{"id":729691,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Stock Option (Right to buy)","published_at":"2026-06-23T21:52:00.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"security","element":"securityTitle","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common stock, $0.0001 par value","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0000921895-26-001653","document":"form407422010_06232026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001653/form407422010_06232026.xml","form_type":"4"}},{"id":731131,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option to Buy","published_at":"2026-06-22T20:50:38.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":22195,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to Spike Loy's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":22195,"derivative":{"exercise_price":19.19,"expiration_date":"2036-06-17","underlying":"Class A Ordinary Shares, $0.0001 par value","underlying_shares":22195},"source":{"system":"sec-edgar","filing":"0000921895-26-001639","document":"form407422mltx_06222026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001639/form407422mltx_06222026.xml","form_type":"4"}},{"id":776112,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series X Convertible Preferred Stock","published_at":"2026-05-18T21:29:45.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":false,"shares":772,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein are exempt from Section 16(b) by virtue of Rule 16b-6(b)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series X Convertible Preferred Stock are exercisable immediately do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series X Convertible Preferred Stock are exercisable immediately do not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities held in certain Partners managed accounts (the \"Partners Managed Accounts\"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities held in certain Partners managed accounts (the \"Partners Managed Accounts\"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts."}],"balance_after":0,"derivative":{"exercise_price":4.03,"underlying":"Common Stock, $0.0075 par value per share","underlying_shares":772000},"source":{"system":"sec-edgar","filing":"0000921895-26-001435","document":"form407422xoma_05182026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001435/form407422xoma_05182026.xml","form_type":"4"}},{"id":776111,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series X Convertible Preferred Stock","published_at":"2026-05-18T21:29:45.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":false,"shares":412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein are exempt from Section 16(b) by virtue of Rule 16b-6(b)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series X Convertible Preferred Stock are exercisable immediately do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series X Convertible Preferred Stock are exercisable immediately do not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":0,"derivative":{"exercise_price":4.03,"underlying":"Common Stock, $0.0075 par value per share","underlying_shares":412000},"source":{"system":"sec-edgar","filing":"0000921895-26-001435","document":"form407422xoma_05182026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001435/form407422xoma_05182026.xml","form_type":"4"}},{"id":776110,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series X Convertible Preferred Stock","published_at":"2026-05-18T21:29:45.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":false,"shares":1506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein are exempt from Section 16(b) by virtue of Rule 16b-6(b)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series X Convertible Preferred Stock are exercisable immediately do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series X Convertible Preferred Stock are exercisable immediately do not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":0,"derivative":{"exercise_price":4.03,"underlying":"Common Stock, $0.0075 par value per share","underlying_shares":1506000},"source":{"system":"sec-edgar","filing":"0000921895-26-001435","document":"form407422xoma_05182026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001435/form407422xoma_05182026.xml","form_type":"4"}},{"id":776109,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series X Convertible Preferred Stock","published_at":"2026-05-18T21:29:45.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":false,"shares":2313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein are exempt from Section 16(b) by virtue of Rule 16b-6(b)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series X Convertible Preferred Stock are exercisable immediately do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series X Convertible Preferred Stock are exercisable immediately do not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":0,"derivative":{"exercise_price":4.03,"underlying":"Common Stock, $0.0075 par value per share","underlying_shares":2313000},"source":{"system":"sec-edgar","filing":"0000921895-26-001435","document":"form407422xoma_05182026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001435/form407422xoma_05182026.xml","form_type":"4"}},{"id":776108,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2026-05-18T21:29:45.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":true,"shares":772000,"price":4.03,"value":3111160.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein are exempt from Section 16(b) by virtue of Rule 16b-6(b)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities held in certain Partners managed accounts (the \"Partners Managed Accounts\"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities held in certain Partners managed accounts (the \"Partners Managed Accounts\"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts."}],"balance_after":772000,"source":{"system":"sec-edgar","filing":"0000921895-26-001435","document":"form407422xoma_05182026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001435/form407422xoma_05182026.xml","form_type":"4"}},{"id":776107,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2026-05-18T21:29:45.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":true,"shares":412000,"price":4.03,"value":1660360.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein are exempt from Section 16(b) by virtue of Rule 16b-6(b)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":412000,"source":{"system":"sec-edgar","filing":"0000921895-26-001435","document":"form407422xoma_05182026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001435/form407422xoma_05182026.xml","form_type":"4"}},{"id":776106,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2026-05-18T21:29:45.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":true,"shares":1506000,"price":4.03,"value":6069180.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein are exempt from Section 16(b) by virtue of Rule 16b-6(b)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2773545,"source":{"system":"sec-edgar","filing":"0000921895-26-001435","document":"form407422xoma_05182026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001435/form407422xoma_05182026.xml","form_type":"4"}},{"id":776105,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2026-05-18T21:29:45.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":true,"shares":2313000,"price":4.03,"value":9321390.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein are exempt from Section 16(b) by virtue of Rule 16b-6(b)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3635758,"source":{"system":"sec-edgar","filing":"0000921895-26-001435","document":"form407422xoma_05182026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189526001435/form407422xoma_05182026.xml","form_type":"4"}},{"id":821456,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares, $0.0001 par value","published_at":"2026-04-02T20:48:05.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":248530,"price":16.79,"value":4172818.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":1039238,"source":{"system":"sec-edgar","filing":"0000921895-26-000895","document":"form407422mltx_04022026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526000895/form407422mltx_04022026.xml","form_type":"4"}},{"id":821455,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares, $0.0001 par value","published_at":"2026-04-02T20:48:05.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":1569116,"price":16.79,"value":26345457.64,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":6599722,"source":{"system":"sec-edgar","filing":"0000921895-26-000895","document":"form407422mltx_04022026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526000895/form407422mltx_04022026.xml","form_type":"4"}},{"id":821454,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares, $0.0001 par value","published_at":"2026-04-02T20:48:05.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":1932354,"price":16.79,"value":32444223.66,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general parter of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":8302735,"source":{"system":"sec-edgar","filing":"0000921895-26-000895","document":"form407422mltx_04022026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526000895/form407422mltx_04022026.xml","form_type":"4"}},{"id":927466,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2026-01-30T23:44:11.000Z","date":"2026-01-28","kind":"other","planned":false,"acquired":false,"shares":548938,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an Arrangement Agreement, dated as of November 14, 2025, under the Business Corporations Act (Quebec), by and among the Issuer, XenoTherapeutics, Inc. (\"Parent\"), Xeno Acquisition Corp. (\"Purchaser\"), a wholly-owned subsidiary of Parent, and solely for limited purposes, XOMA Royalty Corporation, pursuant to to which Purchaser acquired all of the issued and outstanding Common Shares of the Issuer, effective January 28, 2026 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Reporting Persons received the following in exchange for each Common Share of the Issuer disposed of in connection with the Merger: $2.20 in cash per Common Share and one contingent value right per Common Share for potential cash payments."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-26-000173","document":"form407422010_01302026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526000173/form407422010_01302026.xml","form_type":"4"}},{"id":927465,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2026-01-30T23:44:11.000Z","date":"2026-01-28","kind":"other","planned":false,"acquired":false,"shares":4308573,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an Arrangement Agreement, dated as of November 14, 2025, under the Business Corporations Act (Quebec), by and among the Issuer, XenoTherapeutics, Inc. (\"Parent\"), Xeno Acquisition Corp. (\"Purchaser\"), a wholly-owned subsidiary of Parent, and solely for limited purposes, XOMA Royalty Corporation, pursuant to to which Purchaser acquired all of the issued and outstanding Common Shares of the Issuer, effective January 28, 2026 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Reporting Persons received the following in exchange for each Common Share of the Issuer disposed of in connection with the Merger: $2.20 in cash per Common Share and one contingent value right per Common Share for potential cash payments."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-26-000173","document":"form407422010_01302026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526000173/form407422010_01302026.xml","form_type":"4"}},{"id":927464,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2026-01-30T23:44:11.000Z","date":"2026-01-28","kind":"other","planned":false,"acquired":false,"shares":5309432,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an Arrangement Agreement, dated as of November 14, 2025, under the Business Corporations Act (Quebec), by and among the Issuer, XenoTherapeutics, Inc. (\"Parent\"), Xeno Acquisition Corp. (\"Purchaser\"), a wholly-owned subsidiary of Parent, and solely for limited purposes, XOMA Royalty Corporation, pursuant to to which Purchaser acquired all of the issued and outstanding Common Shares of the Issuer, effective January 28, 2026 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Reporting Persons received the following in exchange for each Common Share of the Issuer disposed of in connection with the Merger: $2.20 in cash per Common Share and one contingent value right per Common Share for potential cash payments."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-26-000173","document":"form407422010_01302026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526000173/form407422010_01302026.xml","form_type":"4"}},{"id":1019695,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T21:33:13.000Z","date":"2025-10-09","kind":"other","planned":false,"acquired":false,"shares":560797,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an arrangement under Section 288 of the Business Corporations Act (British Columbia) involving the Issuer, XenoTherapeutics, Inc. (the \"Parent\"), Xeno Acquisition Corp. (the \"Purchaser\"), a wholly-owned subsidiary of Parent, and XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025, and the plan of arrangement, pursuant to which, among other things, the Purchaser acquired all of the outstanding shares of common stock of the Issuer, effective October 9, 2025 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $0.124231 in cash per share of common stock (excluding the approximately $1.69 of cash per share of common stock previously distributed to the Issuer's shareholders) and one contingent value right per share of common stock for potential cash payments of up to approximately $0.14 per share of common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002742","document":"form407422epix_10142025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002742/form407422epix_10142025.xml","form_type":"4"}},{"id":1019694,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T21:33:13.000Z","date":"2025-10-09","kind":"other","planned":false,"acquired":false,"shares":4726743,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an arrangement under Section 288 of the Business Corporations Act (British Columbia) involving the Issuer, XenoTherapeutics, Inc. (the \"Parent\"), Xeno Acquisition Corp. (the \"Purchaser\"), a wholly-owned subsidiary of Parent, and XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025, and the plan of arrangement, pursuant to which, among other things, the Purchaser acquired all of the outstanding shares of common stock of the Issuer, effective October 9, 2025 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $0.124231 in cash per share of common stock (excluding the approximately $1.69 of cash per share of common stock previously distributed to the Issuer's shareholders) and one contingent value right per share of common stock for potential cash payments of up to approximately $0.14 per share of common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002742","document":"form407422epix_10142025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002742/form407422epix_10142025.xml","form_type":"4"}},{"id":1019693,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T21:33:13.000Z","date":"2025-10-09","kind":"other","planned":false,"acquired":false,"shares":6194145,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to an arrangement under Section 288 of the Business Corporations Act (British Columbia) involving the Issuer, XenoTherapeutics, Inc. (the \"Parent\"), Xeno Acquisition Corp. (the \"Purchaser\"), a wholly-owned subsidiary of Parent, and XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025, and the plan of arrangement, pursuant to which, among other things, the Purchaser acquired all of the outstanding shares of common stock of the Issuer, effective October 9, 2025 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $0.124231 in cash per share of common stock (excluding the approximately $1.69 of cash per share of common stock previously distributed to the Issuer's shareholders) and one contingent value right per share of common stock for potential cash payments of up to approximately $0.14 per share of common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002742","document":"form407422epix_10142025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002742/form407422epix_10142025.xml","form_type":"4"}},{"id":1072666,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"other","planned":false,"acquired":false,"shares":203336,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":203336},"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1072665,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"other","planned":false,"acquired":false,"shares":1235030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1235030},"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1072664,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"other","planned":false,"acquired":false,"shares":1481634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1481634},"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1072663,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"sale","planned":false,"acquired":false,"shares":11,"price":1.8779,"value":20.6569,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":560797,"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1072662,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"sale","planned":false,"acquired":false,"shares":66,"price":1.8779,"value":123.9414,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":4726743,"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1072661,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"sale","planned":false,"acquired":false,"shares":79,"price":1.8779,"value":148.3541,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":6194145,"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1072660,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"other","planned":false,"acquired":true,"shares":203336,"price":0.0001,"value":20.3336,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":560808,"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1072659,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"other","planned":false,"acquired":true,"shares":1235030,"price":0.0001,"value":123.503,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":4726809,"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1072658,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-07T20:36:00.000Z","date":"2025-08-05","kind":"other","planned":false,"acquired":true,"shares":1481634,"price":0.0001,"value":148.1634,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":6194224,"source":{"system":"sec-edgar","filing":"0000921895-25-002133","document":"form407422epix_08072025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525002133/form407422epix_08072025.xml","form_type":"4"}},{"id":1098522,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-01T22:41:37.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":16000,"derivative":{"exercise_price":46.47,"expiration_date":"2035-06-24","underlying":"Common Stock, $0.0001 par value","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000921895-25-001910","document":"form407422010_07012025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001910/form407422010_07012025.xml","form_type":"4"}},{"id":1098521,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2025-07-01T22:41:37.000Z","date":"2025-06-30","kind":"purchase","planned":false,"acquired":true,"shares":58780,"price":44,"value":2586320.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F6","text":"Shares of the Issuer's common stock acquired in the Issuer's underwritten public offering at the public offering price of $44.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":353412,"source":{"system":"sec-edgar","filing":"0000921895-25-001910","document":"form407422010_07012025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001910/form407422010_07012025.xml","form_type":"4"}},{"id":1098520,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2025-07-01T22:41:37.000Z","date":"2025-06-30","kind":"purchase","planned":false,"acquired":true,"shares":115783,"price":44,"value":5094452.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F6","text":"Shares of the Issuer's common stock acquired in the Issuer's underwritten public offering at the public offering price of $44.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2219858,"source":{"system":"sec-edgar","filing":"0000921895-25-001910","document":"form407422010_07012025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001910/form407422010_07012025.xml","form_type":"4"}},{"id":1098519,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2025-07-01T22:41:37.000Z","date":"2025-06-30","kind":"purchase","planned":false,"acquired":true,"shares":142604,"price":44,"value":6274576.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F6","text":"Shares of the Issuer's common stock acquired in the Issuer's underwritten public offering at the public offering price of $44.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":2798795,"source":{"system":"sec-edgar","filing":"0000921895-25-001910","document":"form407422010_07012025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001910/form407422010_07012025.xml","form_type":"4"}},{"id":1108869,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":25944,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":25944,"derivative":{"underlying":"Common Stock","underlying_shares":25944},"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108868,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":257515,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":257515,"derivative":{"underlying":"Common Stock","underlying_shares":257515},"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108867,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":304098,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":304098,"derivative":{"underlying":"Common Stock","underlying_shares":304098},"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108866,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":56079,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":62383,"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108865,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":556617,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":593740,"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1108864,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:53:03.000Z","date":"2025-06-13","kind":"other","planned":false,"acquired":true,"shares":657308,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 13, 2025, the Issuer completed a reverse merger transaction (the \"Merger\") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the \"Pre-Funded Warrants\"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":707116,"source":{"system":"sec-edgar","filing":"0000921895-25-001784","document":"form407422010_06172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001784/form407422010_06172025.xml","form_type":"4"}},{"id":1112496,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Stock Option (Right to buy)","published_at":"2025-06-13T22:23:00.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common stock, $0.0001 par value","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0000921895-25-001761","document":"form407422010_06132025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001761/form407422010_06132025.xml","form_type":"4"}},{"id":1118778,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option to Buy","published_at":"2025-06-09T23:16:08.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6682,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to Spike Loy's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":6682,"derivative":{"exercise_price":48.83,"expiration_date":"2035-06-05","underlying":"Class A Ordinary Shares, $0.0001 par value","underlying_shares":6682},"source":{"system":"sec-edgar","filing":"0000921895-25-001730","document":"form407422010_06092025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001730/form407422010_06092025.xml","form_type":"4"}},{"id":1141313,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2025-05-20T22:56:41.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":265316,"price":27.1,"value":7190063.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":1267545,"source":{"system":"sec-edgar","filing":"0000921895-25-001602","document":"form407422010_05202025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189525001602/form407422010_05202025.xml","form_type":"4"}},{"id":1141312,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2025-05-20T22:56:41.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":127407,"price":27.1,"value":3452729.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":1322758,"source":{"system":"sec-edgar","filing":"0000921895-25-001602","document":"form407422010_05202025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189525001602/form407422010_05202025.xml","form_type":"4"}},{"id":1143818,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2025-05-19T22:45:29.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":855211,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. in exchange for $0.33 in cash per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. in exchange for $0.33 in cash per share of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-001590","document":"form407422010_05192025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001590/form407422010_05192025.xml","form_type":"4"}},{"id":1143817,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2025-05-19T22:45:29.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6777935,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. in exchange for $0.33 in cash per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. in exchange for $0.33 in cash per share of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-001590","document":"form407422010_05192025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001590/form407422010_05192025.xml","form_type":"4"}},{"id":1143816,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2025-05-19T22:45:29.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8679726,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. in exchange for $0.33 in cash per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. in exchange for $0.33 in cash per share of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-001590","document":"form407422010_05192025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001590/form407422010_05192025.xml","form_type":"4"}},{"id":1293752,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2025-01-28T22:23:33.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":149975,"price":26.1,"value":3914347.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Subsequent to the Form 4 filed by the Reporting Persons on May 19, 2023, the Reporting Persons ceased to have a pecuniary interest in the securities of the Issuer held by Matthew D. Perry."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities held in certain Partners managed accounts (the \"Partners Managed Accounts\"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities held in certain Partners managed accounts (the \"Partners Managed Accounts\"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-000177","document":"form407422010_01282025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189525000177/form407422010_01282025.xml","form_type":"4"}},{"id":1293751,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2025-01-28T22:23:33.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":75287,"price":26.1,"value":1964990.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Subsequent to the Form 4 filed by the Reporting Persons on May 19, 2023, the Reporting Persons ceased to have a pecuniary interest in the securities of the Issuer held by Matthew D. Perry."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-000177","document":"form407422010_01282025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189525000177/form407422010_01282025.xml","form_type":"4"}},{"id":1293750,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2025-01-28T22:23:33.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":85776,"price":26.1,"value":2238753.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Subsequent to the Form 4 filed by the Reporting Persons on May 19, 2023, the Reporting Persons ceased to have a pecuniary interest in the securities of the Issuer held by Matthew D. Perry."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":1532861,"source":{"system":"sec-edgar","filing":"0000921895-25-000177","document":"form407422010_01282025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189525000177/form407422010_01282025.xml","form_type":"4"}},{"id":1293749,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0075 par value per share","published_at":"2025-01-28T22:23:33.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":339679,"price":26.1,"value":8865621.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Subsequent to the Form 4 filed by the Reporting Persons on May 19, 2023, the Reporting Persons ceased to have a pecuniary interest in the securities of the Issuer held by Matthew D. Perry."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":1450165,"source":{"system":"sec-edgar","filing":"0000921895-25-000177","document":"form407422010_01282025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000092189525000177/form407422010_01282025.xml","form_type":"4"}},{"id":1303908,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2025-01-14T23:38:56.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":22740,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":336288,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":22740},"source":{"system":"sec-edgar","filing":"0000921895-25-000106","document":"form407422010_01142025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525000106/form407422010_01142025.xml","form_type":"4"}},{"id":1303907,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2025-01-14T23:38:56.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":161810,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2627590,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":161810},"source":{"system":"sec-edgar","filing":"0000921895-25-000106","document":"form407422010_01142025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525000106/form407422010_01142025.xml","form_type":"4"}},{"id":1303906,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2025-01-14T23:38:56.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":235450,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3291004,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":235450},"source":{"system":"sec-edgar","filing":"0000921895-25-000106","document":"form407422010_01142025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525000106/form407422010_01142025.xml","form_type":"4"}},{"id":1303905,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common stock, $0.0001 par value","published_at":"2025-01-14T23:38:56.000Z","date":"2025-01-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22740,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":347970,"source":{"system":"sec-edgar","filing":"0000921895-25-000106","document":"form407422010_01142025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525000106/form407422010_01142025.xml","form_type":"4"}},{"id":1303904,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common stock, $0.0001 par value","published_at":"2025-01-14T23:38:56.000Z","date":"2025-01-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":161810,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2003966,"source":{"system":"sec-edgar","filing":"0000921895-25-000106","document":"form407422010_01142025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525000106/form407422010_01142025.xml","form_type":"4"}},{"id":1303903,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common stock, $0.0001 par value","published_at":"2025-01-14T23:38:56.000Z","date":"2025-01-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":235450,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":2655977,"source":{"system":"sec-edgar","filing":"0000921895-25-000106","document":"form407422010_01142025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525000106/form407422010_01142025.xml","form_type":"4"}},{"id":1329809,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.001 par value","published_at":"2024-12-17T22:44:27.000Z","date":"2024-12-13","kind":"other","planned":false,"acquired":true,"shares":29648,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 13, 2024, Palvella Therapeutics, Inc., formerly known as Pieris Pharmaceuticals, Inc. (the \"Issuer\"), completed a reverse merger transaction (the \"Merger\") with Palvella Therapeutics, Inc. (\"Former Palvella\") pursuant to that certain Agreement and Plan of Merger, dated as of July 23, 2024 (the \"Merger Agreement\"). In connection with the Merger, the Reporting Persons acquired an aggregate of 438,929 shares of Common Stock in exchange for all of the Former Palvella capital stock owned of record by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 13, 2024, Palvella Therapeutics, Inc., formerly known as Pieris Pharmaceuticals, Inc. (the \"Issuer\"), completed a reverse merger transaction (the \"Merger\") with Palvella Therapeutics, Inc. (\"Former Palvella\") pursuant to that certain Agreement and Plan of Merger, dated as of July 23, 2024 (the \"Merger Agreement\"). In connection with the Merger, the Reporting Persons acquired an aggregate of 438,929 shares of Common Stock in exchange for all of the Former Palvella capital stock owned of record by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"Reflects an eighty-for-one reverse stock split of the Issuer's issued and outstanding Common Stock, effective as of April 18, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":38961,"source":{"system":"sec-edgar","filing":"0000921895-24-002972","document":"form407422010_12172024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002972/form407422010_12172024.xml","form_type":"4"}},{"id":1329808,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.001 par value","published_at":"2024-12-17T22:44:27.000Z","date":"2024-12-13","kind":"other","planned":false,"acquired":true,"shares":174958,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 13, 2024, Palvella Therapeutics, Inc., formerly known as Pieris Pharmaceuticals, Inc. (the \"Issuer\"), completed a reverse merger transaction (the \"Merger\") with Palvella Therapeutics, Inc. (\"Former Palvella\") pursuant to that certain Agreement and Plan of Merger, dated as of July 23, 2024 (the \"Merger Agreement\"). In connection with the Merger, the Reporting Persons acquired an aggregate of 438,929 shares of Common Stock in exchange for all of the Former Palvella capital stock owned of record by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 13, 2024, Palvella Therapeutics, Inc., formerly known as Pieris Pharmaceuticals, Inc. (the \"Issuer\"), completed a reverse merger transaction (the \"Merger\") with Palvella Therapeutics, Inc. (\"Former Palvella\") pursuant to that certain Agreement and Plan of Merger, dated as of July 23, 2024 (the \"Merger Agreement\"). In connection with the Merger, the Reporting Persons acquired an aggregate of 438,929 shares of Common Stock in exchange for all of the Former Palvella capital stock owned of record by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"Reflects an eighty-for-one reverse stock split of the Issuer's issued and outstanding Common Stock, effective as of April 18, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":282223,"source":{"system":"sec-edgar","filing":"0000921895-24-002972","document":"form407422010_12172024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002972/form407422010_12172024.xml","form_type":"4"}},{"id":1329807,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.001 par value","published_at":"2024-12-17T22:44:27.000Z","date":"2024-12-13","kind":"other","planned":false,"acquired":true,"shares":234323,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 13, 2024, Palvella Therapeutics, Inc., formerly known as Pieris Pharmaceuticals, Inc. (the \"Issuer\"), completed a reverse merger transaction (the \"Merger\") with Palvella Therapeutics, Inc. (\"Former Palvella\") pursuant to that certain Agreement and Plan of Merger, dated as of July 23, 2024 (the \"Merger Agreement\"). In connection with the Merger, the Reporting Persons acquired an aggregate of 438,929 shares of Common Stock in exchange for all of the Former Palvella capital stock owned of record by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 13, 2024, Palvella Therapeutics, Inc., formerly known as Pieris Pharmaceuticals, Inc. (the \"Issuer\"), completed a reverse merger transaction (the \"Merger\") with Palvella Therapeutics, Inc. (\"Former Palvella\") pursuant to that certain Agreement and Plan of Merger, dated as of July 23, 2024 (the \"Merger Agreement\"). In connection with the Merger, the Reporting Persons acquired an aggregate of 438,929 shares of Common Stock in exchange for all of the Former Palvella capital stock owned of record by the Reporting Persons."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"Reflects an eighty-for-one reverse stock split of the Issuer's issued and outstanding Common Stock, effective as of April 18, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":371916,"source":{"system":"sec-edgar","filing":"0000921895-24-002972","document":"form407422010_12172024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002972/form407422010_12172024.xml","form_type":"4"}},{"id":1343736,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":160107,"price":9.0799,"value":1453755.5493,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"Private Placement\") shares of Common Stock of the Issuer or Pre-Funded Warrants in lieu thereof. In connection with the Private Placement, BVF, BVF2 and Trading Fund OS acquired Pre-Funded Warrants to purchase 1,258,027 shares, 1,047,044 shares and 160,107 shares, respectively. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":313548,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":160107},"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1343735,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":1047044,"price":9.0799,"value":9507054.8156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"Private Placement\") shares of Common Stock of the Issuer or Pre-Funded Warrants in lieu thereof. In connection with the Private Placement, BVF, BVF2 and Trading Fund OS acquired Pre-Funded Warrants to purchase 1,258,027 shares, 1,047,044 shares and 160,107 shares, respectively. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2465780,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":1047044},"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1343734,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":1258027,"price":9.0799,"value":11422759.3573,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"Private Placement\") shares of Common Stock of the Issuer or Pre-Funded Warrants in lieu thereof. In connection with the Private Placement, BVF, BVF2 and Trading Fund OS acquired Pre-Funded Warrants to purchase 1,258,027 shares, 1,047,044 shares and 160,107 shares, respectively. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3055554,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":1258027},"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1343733,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":153441,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":153441,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":153441},"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1343732,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":1418736,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":1418736,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":1418736},"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1343731,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":1797527,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":1797527,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":1797527},"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1343730,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common stock, $0.0001 par value","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":153441,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":370710,"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1343729,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common stock, $0.0001 par value","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1418736,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2165776,"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1343728,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common stock, $0.0001 par value","published_at":"2024-12-05T00:55:22.000Z","date":"2024-12-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1797527,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 3,420,000 shares of Common Stock of the Issuer for a total of 3,420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 1,797,527 shares for 1,797,527 Pre-Funded Warrants, BVF2 exchanged 1,418,736 shares for 1,418,736 Pre-Funded Warrants and Trading Fund OS exchanged 153,441 shares for 153,441 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":2891427,"source":{"system":"sec-edgar","filing":"0000921895-24-002886","document":"form407422010_12042024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002886/form407422010_12042024.xml","form_type":"4"}},{"id":1367388,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":true,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":240000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock, $0.0001 par value","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367387,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":true,"shares":2378000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2378000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock, $0.0001 par value","underlying_shares":2378000},"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367386,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":true,"shares":3062000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3062000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock, $0.0001 par value","underlying_shares":3062000},"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367385,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":false,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":87911,"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367384,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":false,"shares":2378000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":662970,"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1367383,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-11-13T21:33:15.000Z","date":"2024-11-08","kind":"other","planned":false,"acquired":false,"shares":3062000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":830237,"source":{"system":"sec-edgar","filing":"0000921895-24-002631","document":"form407422010_11132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002631/form407422010_11132024.xml","form_type":"4"}},{"id":1379062,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock","published_at":"2024-10-31T21:53:21.000Z","date":"2024-10-29","kind":"sale","planned":false,"acquired":false,"shares":64617,"price":14.3,"value":924023.1,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":176692,"source":{"system":"sec-edgar","filing":"0000921895-24-002409","document":"form407422thrd_10312024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002409/form407422thrd_10312024.xml","form_type":"4"}},{"id":1379061,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock","published_at":"2024-10-31T21:53:21.000Z","date":"2024-10-29","kind":"sale","planned":false,"acquired":false,"shares":396963,"price":14.3,"value":5676570.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":1367257,"source":{"system":"sec-edgar","filing":"0000921895-24-002409","document":"form407422thrd_10312024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002409/form407422thrd_10312024.xml","form_type":"4"}},{"id":1379060,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Common Stock","published_at":"2024-10-31T21:53:21.000Z","date":"2024-10-29","kind":"sale","planned":false,"acquired":false,"shares":538420,"price":14.3,"value":7699406.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially the own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":1794218,"source":{"system":"sec-edgar","filing":"0000921895-24-002409","document":"form407422thrd_10312024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002409/form407422thrd_10312024.xml","form_type":"4"}},{"id":1379059,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-10-31T21:52:16.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":440489,"price":3.649,"value":1607344.361,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":838507,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":440489},"source":{"system":"sec-edgar","filing":"0000921895-24-002408","document":"form407422eldn_10312024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002408/form407422eldn_10312024.xml","form_type":"4"}},{"id":1379058,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-10-31T21:52:16.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":2100244,"price":3.649,"value":7663790.356,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":6235545,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":2100244},"source":{"system":"sec-edgar","filing":"0000921895-24-002408","document":"form407422eldn_10312024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002408/form407422eldn_10312024.xml","form_type":"4"}},{"id":1379057,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-10-31T21:52:16.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":2213816,"price":3.649,"value":8078214.584,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":7415596,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":2213816},"source":{"system":"sec-edgar","filing":"0000921895-24-002408","document":"form407422eldn_10312024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002408/form407422eldn_10312024.xml","form_type":"4"}},{"id":1389637,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares, $0.0001 par value","published_at":"2024-10-08T22:50:12.000Z","date":"2024-10-04","kind":"sale","planned":false,"acquired":false,"shares":132549,"price":50.0016,"value":6627662.0784,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":1287768,"source":{"system":"sec-edgar","filing":"0000921895-24-002263","document":"form407422010_10082024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002263/form407422010_10082024.xml","form_type":"4"}},{"id":1389636,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares, $0.0001 par value","published_at":"2024-10-08T22:50:12.000Z","date":"2024-10-04","kind":"sale","planned":false,"acquired":false,"shares":836862,"price":50.0016,"value":41844438.9792,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":8168838,"source":{"system":"sec-edgar","filing":"0000921895-24-002263","document":"form407422010_10082024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002263/form407422010_10082024.xml","form_type":"4"}},{"id":1389635,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares, $0.0001 par value","published_at":"2024-10-08T22:50:12.000Z","date":"2024-10-04","kind":"sale","planned":false,"acquired":false,"shares":1030589,"price":50.0016,"value":51531098.9424,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general parter of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":10235089,"source":{"system":"sec-edgar","filing":"0000921895-24-002263","document":"form407422010_10082024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002263/form407422010_10082024.xml","form_type":"4"}},{"id":1425941,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2024-08-22T21:06:14.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":156742,"price":40.7499,"value":6387220.8258,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":156742,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock, $0.0001 par value","underlying_shares":156742},"source":{"system":"sec-edgar","filing":"0000921895-24-001896","document":"form407422010_08222024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001896/form407422010_08222024.xml","form_type":"4"}},{"id":1425940,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2024-08-22T21:06:14.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":201546,"price":40.7499,"value":8212979.3454,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":201546,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock, $0.0001 par value","underlying_shares":201546},"source":{"system":"sec-edgar","filing":"0000921895-24-001896","document":"form407422010_08222024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001896/form407422010_08222024.xml","form_type":"4"}},{"id":1467647,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T21:05:36.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":16000,"derivative":{"exercise_price":31.2,"expiration_date":"2034-06-17","underlying":"Common Stock, $0.0001 par value","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000921895-24-001488","document":"form407422010_06282024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001488/form407422010_06282024.xml","form_type":"4"}},{"id":1476269,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-18T21:31:40.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":23000,"derivative":{"exercise_price":12.36,"expiration_date":"2034-06-14","underlying":"Common stock, $0.0001 par value","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000921895-24-001437","document":"form407422010_06182024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001437/form407422010_06182024.xml","form_type":"4"}},{"id":1485611,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option to Buy","published_at":"2024-06-10T21:06:41.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7688,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Spike Loy's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":7688,"derivative":{"exercise_price":42.44,"expiration_date":"2034-06-06","underlying":"Class A Ordinary Shares, $0.0001 par value","underlying_shares":7688},"source":{"system":"sec-edgar","filing":"0000921895-24-001377","document":"form407422010_06102024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001377/form407422010_06102024.xml","form_type":"4"}},{"id":1519698,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":232068,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":232068,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":232068},"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}},{"id":1519697,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":2526238,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2526238,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":2526238},"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}},{"id":1519696,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":3173135,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3173135,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":3173135},"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}}],"next_cursor":"2024-05-13T21:04:15.000000Z,1519696"}